Skip to main content
. Author manuscript; available in PMC: 2015 Sep 15.
Published in final edited form as: J Neuroimmunol. 2014 Jun 27;274(0):71–77. doi: 10.1016/j.jneuroim.2014.06.021

Figure 4. STI1 expression in GAMs and infiltrating lymphocytes is modulated by the brain tumor microenvironment.

Figure 4

(A) Flow cytometry wasperformed to identify STI1–positive inflammatory cells in GL261 tumors propagated in either the brain or subcutaneous tissue. Representative dot plots demonstrating the expression of STI1 in monocytes/macrophages (Mon/MP; CD11b+/CD45high) and lymphocytes (Lym; CD11b−/CD45+) after gating the CD45+ (leukocyte) population. The size of the tumors is identified in each dot plot. B, D and F: brain tumors (n=15 mice in total); C, E and G: subcutaneous tumors (n=13 mice in total). Y axis: percentage of microglia (MG), monocytes/macrophages (Mon/MP) and lymphocytes (Lym) positives for STI1; X axis: tumor area (mm2) or volume (mm3). Brain, blood and subcutaneous tissue (SC) were analyzed. The thicker lines are the result of a linear regression from each of the curves.